Merck & Co., Inc. Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Merck & Co., Inc. stock.
View analyst ratings for Merck & Co., Inc. or view top-rated stocks.

Wall Street analysts have given Merck & Co., Inc. a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Merck & Co., Inc. wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Merck & Co., Inc. saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 22,070,000 shares, an increase of 17.2% from the May 31st total of 18,830,000 shares. Based on an average daily trading volume, of 11,710,000 shares, the short-interest ratio is currently 1.9 days.
View Merck & Co., Inc.'s Short Interest.

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. will be holding an earnings conference call on Thursday, July 29th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Merck & Co., Inc. (NYSE:MRK) posted its quarterly earnings data on Thursday, April, 29th. The company reported $1.40 EPS for the quarter, missing the consensus estimate of $1.63 by $0.23. The company had revenue of $12.08 billion for the quarter, compared to analyst estimates of $12.71 billion. Merck & Co., Inc. had a net margin of 14.64% and a trailing twelve-month return on equity of 54.15%. The company's quarterly revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.50 EPS.
View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MRK shares have decreased by 1.2% and is now trading at $78.33.
View which stocks have been most impacted by COVID-19.

Merck & Co., Inc. announced a dividend on Tuesday, June 1st. Stockholders of record on Friday, June 4th will be paid a dividend of $0.65 per share on Wednesday, June 2nd. This represents a yield of 3.42%. The ex-dividend date is Thursday, June 3rd.
View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. pays an annual dividend of $2.60 per share and currently has a dividend yield of 3.34%. Merck & Co., Inc. does not yet have a strong track record of dividend growth. The dividend payout ratio of Merck & Co., Inc. is 43.77%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 41.34% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.
View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. updated its FY 2021 earnings guidance on Thursday, May, 6th. The company provided earnings per share (EPS) guidance of 6.480-6.680 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.570. The company issued revenue guidance of $51.80 billion-$53.80 billion, compared to the consensus revenue estimate of $52.51 billion.

11 analysts have issued 12 month target prices for Merck & Co., Inc.'s shares. Their forecasts range from $76.79 to $105.00. On average, they anticipate Merck & Co., Inc.'s share price to reach $94.47 in the next twelve months. This suggests a possible upside of 20.6% from the stock's current price.
View analysts' price targets for Merck & Co., Inc. or view top-rated stocks among Wall Street analysts.

1,343 employees have rated Merck & Co., Inc. CEO Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among Merck & Co., Inc.'s employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of MRK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), The Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and The Home Depot (HD).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc.'s stock is owned by a number of institutional and retail investors. Top institutional shareholders include Marathon Asset Management LLP (0.09%), State of Alaska Department of Revenue (0.03%), Manning & Napier Group LLC (0.03%), Cacti Asset Management LLC (0.03%), Oregon Public Employees Retirement Fund (0.02%) and Gofen & Glossberg LLC IL (0.02%). Company insiders that own Merck & Co., Inc. stock include Frank Clyburn, Julie L Gerberding, Richard R Deluca, Robert M Davis, Sanat Chattopadhyay and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Heritage Wealth Advisors, TCW Group Inc., State of Alaska Department of Revenue, Welch & Forbes LLC, Marshall Financial Group LLC, Terril Brothers Inc., Hodges Capital Management Inc., and Raymond James Trust N.A.. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Robert M Davis, and Sanat Chattopadhyay.
View insider buying and selling activity for Merck & Co., Inc. or view top insider-selling stocks.

MRK stock was acquired by a variety of institutional investors in the last quarter, including Marathon Asset Management LLP, Manning & Napier Group LLC, Brookstone Capital Management, Bright Rock Capital Management LLC, Oregon Public Employees Retirement Fund, Allied Investment Advisors LLC, IFM Investors Pty Ltd, and DAVENPORT & Co LLC.
View insider buying and selling activity for Merck & Co., Inc. or or view top insider-buying stocks.

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRK stock can currently be purchased for approximately $78.33.

Merck & Co., Inc. has a market capitalization of $198.34 billion and generates $47.99 billion in revenue each year. The company earns $7.07 billion in net income (profit) each year or $5.94 on an earnings per share basis.

Merck & Co., Inc. employs 74,000 workers across the globe.

Merck & Co., Inc. was founded in 1891.

The official website for Merck & Co., Inc. is www.merck.com.

Merck & Co., Inc. is headquartered at 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at (908) 740-4000 or via email at [email protected]